Compare · MGNX vs XBIT

MGNX vs XBIT

Side-by-side comparison of MacroGenics Inc. (MGNX) and XBiotech Inc. (XBIT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MGNX and XBIT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • MGNX is the larger of the two at $125.3M, about 2.4x XBIT ($52.7M).
  • MGNX has been more active in the news (13 items in the past 4 weeks vs 7 for XBIT).
  • MGNX has more recent analyst coverage (25 ratings vs 0 for XBIT).
MetricMGNXXBIT
Company
MacroGenics Inc.
XBiotech Inc.
Price
-
-
Market cap
$125.3M
$52.7M
1M return
-45.87%
-
1Y return
+41.37%
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2013
2015
News (4w)
13
7
Recent ratings
25
0
MGNX

MacroGenics Inc.

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

XBIT

XBiotech Inc.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and True Human COVID-19 therapy for treating the COVID-19 mutant virus. In addition, the company provides clinical trial contract research operations to conduct two large, double-blind placebo-controlled Phase II clinical studies. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Latest MGNX

Latest XBIT